Member Info for Wisheyedbortum

... is still well under the radar which might not be such a bad thing. I would dearly like the sp to stay where it is until April 2016 where we can load up our ISAs with more chunks of dosh to make the most of what I am sure will be a multi-bagger in the not too distant future. In fact, things could work out very well with the Cambridge production facility being completed in early 2016. I don't think hat there will be a big reaction to the Oct 26th prelims, but the Feb 8th trading update may cause a bit of a stir. Certainly 2016 could see the start of some serious sp movement.

http://www.avacta.com/news/pre-close-trading-update-0

Thanks for that, very interesting.

Prostrate cancer? well, I'm not taking that lying down!

Cantor Fitzgerald has this as a potential 282.6% upside and HL has it as a strong buy, so I thought I'd have a punt.

Blimey, this guy should put a rocket under Avacta!

a look

Nice one, will take at Q.

....is saying that these biotech companies have the capability of changing investor's lives by increasing the value of their investments by huge percentages. There are no certainties in investing, but being aware that most of it is a gamble, one can only narrow the odds by knowing your companies inside out through research and betting on the ones that look the very best. Hence AGL, RENE and AVCT look about as certain as you can get, but only time will tell. I hope that you looked at AVCT because the company reports in October and it should be good.

I subscribe to Red Hot Penny Shares and this article is in an email that I get from that whole outfit ie Money Morning, The Daily Reckoning and Agora etc, so you may not be able to access it. Sorry if you can't.

http://www.dailyreckoning.co.uk/biotech/the-golden-triangle-of-biotech/ I'm afraid I'm not too good with links etc. but this is where it is. GL.

is selling his Biotech alerting service with the promise of 3 biotech company recommendations that are ready to explode over the next 12-18 months, and I am pretty sure one of them sounds like AGL. "A cancer cell sieve being trialled in Vienna." So even He is raving about AGL. Didn't recognize the other two companies.

My sentiments exactly. I'm 100% up, but still hold 100k shares which if turn out to be worthless, so be it.

http://www.genengnews.com/gen-articles/the-antibody-dilemma/5550/

You have to be very careful with a share like AGL. Everything points to a golden future, but sometimes you have to make sure that the sp is up where it is for a good reason. I was in Iofina when everything looked rosy, but the sp plummeted from £2.50 to 20p over a short period of time. Nightmare. I have been following AVCT since I started in 2009, been to the company, met Alastair Smith, very clever and shrewd cookie. Do take a look.

The antibody business is worth $65bn annually worldwide and in theory AVCT could take it all, via partners, but even 10% is not to be sneezed at.

Thanks for finding that clip. Really interesting and encouraging. I have been building three major shareholdings, all, I believe with great potential, if anybody is interested. Obviously AGL, but also AVCT and RENE. As long as there are no unforeseen problems with these companies, I see all three becoming very rewarding indeed.

It's privileged info I'm afraid, although I did enquire. The major shareholders can be found on the website.

Yes, it's in the live RNS above.

The latest release from Chris Miller contains some interesting testimonials about Affimers and although most of it goes straight over my head there does seem to be an indication that this technology is gathering momentum pretty quickly.